Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Key outcomes: Mean weight loss: 14.9% (vs 2.4% placebo) 86.4% of participants achieved 5% loss (vs 31.5% placebo) 50.5% achieved 15% loss (vs 4.9% placebo) SELECT (Lincoff et al., NEJM 2023) added the cardiovascular signature: in 17,604 non-diabetic adults with prior CV history, semaglutide 2.4 mg reduced MACE (CV death, MI, stroke) by 20% over 3 years
Study: Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study
That is not a single unlucky study or a flawed trial design
However, it is important to follow the recommended dosage instructions and consult with a healthcare professional if you are unsure about which medication to take
